PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against PepGen Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its drug candidate PGN-EDO51 and its CONNECT2 study [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased PepGen's securities between March 7, 2024, and March 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen's drug candidate PGN-EDO51 was less safe and effective than claimed [4]. - It is asserted that the CONNECT2 study was deficient for FDA approval and posed dangers to participants [4]. - The company is likely to halt its CONNECT2 study, leading to false and materially misleading public statements throughout the class period [4]. Group 3: Investor Communication - The Schall Law Firm specializes in securities class action lawsuits and encourages affected investors to contact them for assistance [5]. - Investors can reach out to the firm for a free discussion of their rights [3].